EMA Investigating Roche For Failure to Report Drug Side Effects

European drug regulators are investigating whether Roche failed to report side effects and problems associated with a number of different drugs, which may have been linked to more than 15,000 deaths. 

The European Medicines Agency (EMA) announced last week that it has launched a probe into the Swiss pharmaceutical company Roche. The investigation comes as the result of a May report from the UK Medicines Regulatory Agency (MHRA), after an inspection turned up 80,000 adverse event reports for Roche medicines marketed in the United States that had not been forwarded to European regulators.

The reports included 15,161 patient deaths, and the EMA says it is currently unclear whether those deaths were due to side effects of certain Roche drugs or from natural causes.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The EMA says that there is currently no evidence of a particular risk to patient health linked to the adverse event reports. It is also unclear whether any of the reports had been submitted through other channels, like through patients or doctors.

The EMA has called on Roche to ensure that all known adverse event reports are immediately reported to the appropriate European Union authorities and stipulated that Roche must confirm to the EMA that this has been done for both drugs at the clinical trial stage and for drugs already on the market.

Roche has also been required by the EMA to submit a comprehensive action plan by June 27, detailing how it will evaluate and report all of the outstanding cases and prevent a recurrence of its failure to report. The EMA stipulated that it was evaluating of each of the 80,000 unreported adverse event reports.

Roche officials have acknowledged that it was out of compliance with European Union reporting regulations and says that the error was not intentional. The company says it is pursuing corrective action.

Officially known as F. Hoffman-La Roche Ltd., the company is the producer of a number of blockbuster drugs, including Valium, Xenical, Avastin, Boniva and Tamiflu. The company brought in $42.5 billion in revenue in 2011.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Bard Settlement Reached To Resolve Hernia Mesh Lawsuits, With “Multi-Year” Payout Structure
Bard Settlement Reached To Resolve Hernia Mesh Lawsuits, With “Multi-Year” Payout Structure (Posted today)

Lawyers have reached a confidential settlement agreement to resolve tens of thousands of Bard hernia mesh lawsuits after six years of litigation, but individuals must still agree to participate and settle their claims.

Class Action Claims Over Hair Relaxer Risks Cleared To Move Forward by MDL Judge
Class Action Claims Over Hair Relaxer Risks Cleared To Move Forward by MDL Judge (Posted yesterday)

Court rejected a motion to dismiss the hair relaxer class actions lawsuits, which seek economic damages for consumers exposed to toxic chemicals in the products, which are now known to increase the risk of uterine cancer, ovarian cancer and other injuries.